Glaukos delivered solid revenue growth of 32% but faced substantially higher operating losses and depleted cash reserves while expanding operations.
The company appears to be in a growth investment phase, with meaningful revenue expansion accompanied by proportional increases in R&D and SG&A spending that are pressuring profitability. The substantial decline in cash reserves from $170M to $91M, combined with deepening operating losses, suggests the company may need to carefully manage its burn rate or consider additional financing options.
Glaukos showed strong top-line momentum with revenue growing 32% to $507M, while accounts receivable grew notably, indicating robust business activity. However, the company's operating losses deepened meaningfully as SG&A and R&D expenses grew 27% each, outpacing revenue growth. The cash position declined significantly from $170M to $91M, though operating cash flow improved substantially and debt levels decreased, suggesting management is actively investing in growth while maintaining financial discipline.
Receivables surged 78.8% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Operating cash flow surged 75.9% — exceptional cash generation, highest quality earnings signal.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Cash declined 46.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Debt reduced 44.6% — deleveraging strengthens balance sheet and reduces financial risk.
Current liabilities surged 34.8% — significant near-term obligations; verify ability to meet short-term debt.
Strong top-line growth of 32.3% — accelerating demand or successful expansion into new markets.
Net income declined 28.2% — review whether driven by operations, interest costs, or non-recurring items.
R&D investment increased 27.7% — signals commitment to future product development, though near-term margin impact.
SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →